Kobayashi, Satoshi
Fukushima, Taito
Ueno, Makoto
Moriya, Satoshi
Chuma, Makoto
Numata, Kazushi
Tsuruya, Kota
Hirose, Shunji
Kagawa, Tatehiro
Hattori, Nobuhiro
Watanabe, Tsunamasa
Matsunaga, Kotaro
Suzuki, Michihiro
Uojima, Haruki
Hidaka, Hisashi
Kusano, Chika
Suzuki, Motoko
Morimoto, Manabu
Article History
Received: 13 March 2022
Accepted: 27 April 2022
First Online: 7 May 2022
Declarations
:
: Upon being provided explanations about the present study by the attending investigator, each participating patient provided written informed consent. This study was conducted in accordance with the Declaration of Helsinki, Ethical Guidance for Studies in Life Science and Medical Science in Humans (by the Ministry of Education, Culture, Sports, Science and Technology, Japan, and the Ministry of Health, Labour and Welfare, Japan), and related laws and regulations. All patient data were anonymized to protect patient privacy and used only for study purposes. The study conduct was approved by the Institutional Review Board of Kanagawa Cancer Center as well as the Institutional Review Boards of Yokohama City University Medical Center, Tokai University School of Medicine, St. Marianna University School of Medicine, and Kitasato University School of Medicine.
: Not applicable.
: S. Kobayashi received honoraria for speakers’ bureaus from Bayer Yakuhin, Chugai Pharma, Eisai, Eli Lilly, and Co., Takeda Pharma; and M. Ueno received grants from Chugai Pharma and speakers’ bureaus from Chugai Pharma. The other authors declare no conflicts of interest.